Академический Документы
Профессиональный Документы
Культура Документы
Success (%)
0
0
20
40
60
80
20
40
60
80
100
100
De Cleen et al. 1993 Strindberg 1956
Cross-sectional studies
Tronstad et al. 2000
of Endodontic Therapy
Hommez et al. 2002 Peters et al. 2002.
General Population
jhupp@roseman.edu
James G. Hupp, DMD, MS
Modern Endodontics - From
1
2/26/2017
OUTCOMES
1. State reasons and describe strategies for enlarging the cervical portion of the canal to promote straight-line access.
2. Define how to determine the appropriate size of the master apical file.
3. Describe objectives for both cleaning and shaping and explain how to determine when these have been achieved.
4. Describe appropriate techniques for removing the pulp.
5. Characterize the difficulties of preparation in the presence of anatomic aberrations that make complete debridement difficult.
6. List properties of suitable irrigants and identify which irrigant meets most of the criteria.
7. Describe the techniques that provide the maximal irrigant effect.
8. Discuss the properties and role of chelating and decalcifying agents.
9. Explain how to minimize preparation errors in small, curved canals.
10. Describe techniques for negotiating severely curved, blocked, ledged, or constricted canals.
11. Discuss the properties and role of intracanal, interappointment medicaments.
12. List the principal temporary filling materials and describe techniques for their placement and removal.
13. Describe temporization of extensively damaged teeth.
14. Outline techniques and materials used for long-term temporization.
2
2/26/2017
The Prevention of
Apical Periodontitis
Treatment of a vital
(non-infected) pulp
Pathogenisis
Oral microorganisms
3
2/26/2017
Irreversible pulpitis
12
Oral microorganisms
4
2/26/2017
5
2/26/2017
Canal Disinfection
Microbiological Goals
Tx Vital pulps - prophylactic
treatment (pulp free of infection) -
prevent apical periodontitis -
ASEPSIS
Tx Apical periodontitis - infectious
disease that should be treated with
elimination of microorganisms -
ANTISEPSIS
Kievit TR Infect Immuno 2000
Smith T. textbook1934
Diagnosis
Mechanical Antimicrobial
Instrumentation Irrigation
Intra-canal
medication
6
2/26/2017
APICAL SIZE
Asepsis!
Chemo-Mechanical
R.C. Filling
Instrumentation
UPPER JAW
ISO 50 or 60 ISO 50 ISO 50 or 60 B: ISO 35 or 40 B: ISO 35 or 40 MBs: ISO 35 or 40 MBs: ISO 35 or 40
ISO 35- 40 P: ISO 40 P: ISO 40 DB: ISO 35 or 40 DB: ISO 35 or 40
(if curved) P: ISO 50 or 60 P: ISO 50 or 60
1 canal: 1 canal:
ISO 50 or 60 ISO 50 or 60
LOWER JAW
7
2/26/2017
Dentin
Cementum
0.5 to 1.0 mm
Radiographic
apex
D M
B
1 mm - 0.35/0.37 mm
2 mm - 0.41/0.55 mm
3 mm - 0.49/0.54 mm
4 mm - 0.54/0.60 mm
1 mm - 0.22/0.23 mm L
2 mm - 0.27/0.27 mm
D #25 M 3 mm#25
- 0.30/0.30 mm
4 mm - 0.35/0.36 mm
8
2/26/2017
IRRIGATION
5
20% neg.
culture
40% neg.
Log10 CFU means
4
culture
3
2
61.8% neg.
1
40% neg. culture culture
#20 #25 #35
0
S1 S2 S3 S4
samples
McGurkin et al. 2005
9
2/26/2017
Intracanal Irrigation
Needle penetration and diameter
10
2/26/2017
Intracanal Irrigation
IRRIGATION PROTOCOL
*Your endodontic set-up will have a 30g side-vented needle (for final irrigation) and a 23g needle
(for bulk irrigation).
3-5 ml EDTA (Smear Clear) per canal (over 1 minute) This is a flush not a soak! 30 g needle
3 ml 2% CHX per canal as a final rinse 30 g needle
ICM
11
2/26/2017
Ca(OH)2
Ca(OH)2
1-4 weeks
12
2/26/2017
Block of nutrients
Neutralize bacterial
products - LPS
Disrupt Biofilms
Safavi KE, Nichols FC. Effect of calcium hydroxide on bacterial lipo- polysaccharide. J Endodon 1993;19:768.
Safavi KE, Nichols FC. Alteration of biological properties of bacterial lipopolysaccharide by calcium hydroxide treatment. J Endodon
No differences between
1994;20:1279
OBTURATION
13
2/26/2017
Goal of
Penn
Endo Obturation
Penn
Endo
14
2/26/2017
BioCeramics
Ceramic materials that are specially
developed for use as medical
(orthopedic joint replacement -
framework for tissue replacement)
and dental implants
BioCeramics
Alumina and zirconia
Ceramic materials that
Calcium silicate
are specially developed
Calcium oxides
for use as medical
Calcium phosphates
(orthopedic joint
Calcium carbonate
replacement - framework
Bioactive glasses
for tissue replacement)
Glass-ceramics
and dental implants
Hydroxyapatite
BIOCERAMIC TECHNOLOGY
DEFINITION
Ceramics used for the repair and reconstruction of diseased or damaged parts of
the musculo-skeletal system, termed bioceramics, may be bio-inert (alumina,
zirconia), resorbable (tricalcium phosphate), bioactive (hydroxyapatite, bioactive
glasses, and glass-ceramics), or porous for tissue ingrowth (hydroxyapatite-coated
metals, alumina).
MTA
BIODENTIN
E
NANOTECHNOLOGY
PARTICLE SIZE
CALCIUM SILICATES
SETTING REACTION PRODUCES HYDROXYAPATITE
creates the monoblock or chemical bond
15
2/26/2017
BioCeramics in Endo
1st generation
New Generation
of BioCeramics in
Endodontics
48
BioCeramics in Endo
Powder Liquid Time Use
Tricalcium silicate (CaSiO4)
Tricalcium aluminate (CaAl 2O4)
Tricalcium oxide (CaSO4) Distilled water 15 min to 4 Mix before
hours use
MTA Silicate oxide
Bismuth oxide for radiopacity
(BiO3)
pH = 12.8
pH = 12.9
e
Tricalcium silicate (CaSiO4) Moisture from 2-4 hours
periapical and root Ready mixed
16
2/26/2017
Tricalcium Biosilicate
Technology
17
2/26/2017
Bioceramic Points /
Bioceramic sealer
BioCeramics in Endo
Powder Liquid Time Use
Tricalcium silicate (CaSiO4)
Distilled water 15 min to 24 Mix before
Silicate oxide
Bismuth oxide for radiopacity
(BiO3)
pH = 12.8
EndoSequence BC -
Research
More than 40 scientific studies from 2008-2012
Antimicrobial effect
Cytotoxicity
Biocompatibility
Sealability
Adhesion
Clinical
55
18
2/26/2017
Penn
Endo
BC SEALER
BioACTIVE
material during
hydration process
BioSTABLE upon
setting
19
2/26/2017
Penn
Endo BioACTIVE material during hydration
process
Bioactive glass requires an aqueous environment to set
Hydration reactions of calcium silicates: Is this chemical or physical rxn? (assess)
(A) 2[CaOSiO2] + 4H2O 3CaO2SiO23H2O + Ca(OH)2
(B) 3[CaOSiO2] + 6H2O 3CaO2SiO23H2O + 3Ca(OH)2
BIOCERAMIC OBTURATION
1. ANTIBACTERIAL - PH
2. HYDROPHILIC
3. EXPANDS SLIGHTLY
4. DIMENSIONALLY STABLE
5. BIOCOMPATIBLE-0STEOGENIC
20
2/26/2017
BioCeramics in Endodontics
Conclusions
Excellent sealing properties (seal in wet environment)
Potent antibacterial activity (pH - 12.5)
Biocompatible material
Chemical bond with dentine
Insoluble in tissue fluids
Easy handling (last generations)
Can be used on retrograde, orthograde fashoin and as a
obturation material combined with gutta-percha
62
21
2/26/2017
22
2/26/2017
Penn
Endo
Experimental Procedure
Histology
Results
Inflammation rates
G + S + Comp
39% (n=7/18)
M=6, S=1
23
2/26/2017
BIORACE
24
2/26/2017
Taper can be defined as the rate of change of cross-sectional diameter. A file with a taper of 0.02 (2%) increases in diameter at a rate of 0.02mm per running millimeter of leng
Cyclic
Fatigue
Torsional
Fatigue
Tip locks
Cyclic Torsional
Flute deformation
Flexibility Fatigue Fatigue
Taper
Flexibiltiy
Apical Sizes
25
2/26/2017
D16(0.57mm)
Flexible
0.27mm
0.29mm
0.31mm
0.02 25/0.02
D1(0.25mm)
+ 0.06mm per mm
Flexible
0.43mm
0.37mm
0.31mm
D16(1.21mm)
0.06 25/0.06
0.10 Taper
0.08 Taper
0.06 Taper
0.04 Taper
26
2/26/2017
0.04 Taper
# 25
# 30
# 35
# 40
15/0.02
20/0.02
25/0.02
30/0.02
35/0.02
40/0.02
27
2/26/2017
ONE FILE
25/0.08
Micro Cracks
4X gentle
movements
600 rpm
28
2/26/2017
25/16mm
15/0.05
BR1
General 25/0.04
Shape BR2
Full Length
25/0.06
BR3
35/0.04
BR4
Apical
Prep.
Full Length 40/0.04
BR5
21 mm
8 mm
81
41 73 80 77 103 85 92
13 65 75 81 88
39 73 97
12 57 70 79 84
37 69 91
11 49 65 75 80
35 65 85
10 41 60 71 76
33 61 79
09 33 55 67 72
31 57 73
13 mm
08 25 50 63 68
29 53 67
07 45 59 64
27 49 61
06 40 55 60
25 45 55
05 35 51 56
23 41 49
04 30 47 52
21 37 43
03 25 43 48
19 33 37
02 20 39 44
17 29 31
01 15 35 40
15* 25 25
00
mm
21 mm
8 mm
81
41 73 80 77 103 85 92
13 65 75 81 88
39 73 97
12 57 70 79 84
37 69 91
11 49 65 75 80
35 65 85
10 41 60 71 76
33 61 79
09 33 55 67 72
31 57 73
13 mm
08 25 50 63 68
29 53 67
07 45 59 64
27 49 61
06 40 55 60
25 45 55
05 35 51 56
23 41 49
04 30 47 52
21 37 43
03 25 43 48
19 33 37
02 20 39 44
17 29 31
01 15 35 40
15* 25 25
00
mm
29
2/26/2017
BR0 - 25/0.08
19mm BR1 BR2BR3BR4BR5 25/0.06
15/0.05
25/0.04
35/0.04
40/0.04
BR1 - 15/0.05
BR0 BR2BR3BR4BR5
25/0.06
25/0.08
25/0.04
35/0.04
40/0.04
BR2 - 25/0.04
BR0BR1 BR3BR4BR5
25/0.06
15/0.05
25/0.08
35/0.04
40/0.04
30
2/26/2017
BR3 - 25/0.06
BR0BR1 BR2 BR4BR5
15/0.05
25/0.08
25/0.04
35/0.04
40/0.04
BR3
.06 taper
If it doesnt go to WL after first cycle(4x insertions), flush canal, wipe file and repeat cycle
BR4 - 35/0.04
BR0BR1 BR2BR3 BR5
25/0.06
15/0.05
25/0.08
25/0.04
40/0.04
31
2/26/2017
BR5 - 40/0.04
BR0BR1 BR2BR3BR4 25/0.06
15/0.05
25/0.08
25/0.04
35/0.04
Bio RaCe
Extended Set
Large apical
preparation
Bio RaCe
Extended Set
Large apical
preparation
BR7 - 60/0.02
BR6 - 50/0.04
32
2/26/2017
Bio RaCe
Extended Set
Large apical
preparation
BR6 - 50/0.04
BR7 - 60/0.02
7-8 mm
Apical Box
DB:40/0.04
33
2/26/2017
Extended Set
35/0.02 40/0.02
BR4 BR5
BR0
19 mm
BR6 BR7
to BR3
as for
the Basic
set
Additional large
apical sizes
25/0.08 25/0.06
34
2/26/2017
B-L orientation
35
2/26/2017
apex
measure the
radiographic length
reference point
36
2/26/2017
22mm
TREATMENT RECORD
37
2/26/2017
* No need to adjust
38
2/26/2017
* EWL = FWL
* record FWL
TREATMENT RECORD
39